We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SmileDirectClub (SDC) Q2 Loss Wider Than Expected, Margin Up
Read MoreHide Full Article
SmileDirectClub, Inc. reported a loss of 14 cents for second-quarter 2021, narrower than the year-ago loss of 25 cents. The figure was however wider than the Zacks Consensus Estimate of a loss of 10 cents.
Revenues
Revenues in the second quarter totaled $174.2 million, lagging the Zacks Consensus Estimate by 12%. However, the top line improved 62.7% from the year-ago number. The company shipped roughly 90,006 unique aligner orders, down 15.9% sequentially. The quarter’s ASP came in at $1,885, up 1.3% on a sequential basis.
Net revenues (related to retainers, whitening, and other ancillary products) came in at $20 million, primarily driven by the continued expansion of oral care products. Financing revenues (interest associated with SmilePay program) in the reported quarter were $12 million, flat compared to the last-reported quarter.
Margins
Gross profit in the reported quarter was $128.3 million, up 120% from the prior-year quarter. Gross margin of 73.7% expanded 1923 basis points (bps).
SmileDirectClub, Inc. Price, Consensus and EPS Surprise
Meanwhile, marketing and selling expenses rose 177.9% to $95.9 million. General and administrative expenses were $85 million, up 23.8% year over year. The company incurred adjusted operating loss of $52.7 million in the quarter. However, this was narrower than the year-ago operating loss of $44.9 million.
Financial Updates
SmileDirectClub exited the second quarter of 2021 with cash and cash equivalents of $376.6 million compared with $295.3 million at the end of the first quarter of 2021. Total debt (short and long-term) at the end of the second quarter was $744.1 million compared with $655.4 million at the end of first-quarter 2021.
Cumulative net cash flow used in operating activities at the end of the second quarter was $59.4 million compared with $85.8 million a year ago.
Guidance
SmileDirectClub has provided guidance for the year 2021.
For 2021, the company expects total revenues in the range of $750-$800 million. The Zacks Consensus Estimate for the same is pegged at $828.5 million.
Gross margin (as a percentage of total revenues) is expected in the mid-70% range through the second half of 2021.
Our Take
In the second quarter of 2021, SmileDirectClub achieved 62.7% year-over-year growth in total revenues. The company is currently expanding its teledentistry platform to dental and orthodontic offices through a collaborative model. A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives. Expansion of gross margin is encouraging. On the flip side, the company’s second-quarter adjusted loss was wider than the Zacks Consensus Estimate. Financing revenues were flat. The company incurred operating loss in the quarter. Escalating expenses are building pressure on the bottom line. A highly leveraged balance sheet is an added woe.
Zacks Rank and Key Picks
The company currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space that have announced their quarterly results are Encompass Health Corporation (EHC - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
Encompass Health, carrying a Zacks Rank #1 (Strong Buy), reported second-quarter 2021 adjusted earnings per share (EPS) of $1.17, which beat the Zacks Consensus Estimate by 15.8%. Revenues of $1.3 billion outpaced the consensus mark by 1.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2021 adjusted EPS of $2.46, which surpassed the Zacks Consensus Estimate by 41.4%. Revenues of $723.6 million outpaced the Zacks Consensus Estimate by 8.7%.
Henry Schein, carrying a Zacks Rank #2, reported second-quarter 2021 adjusted EPS of $1.11, surpassing the Zacks Consensus Estimate by 16.8%. Revenues of $2.97 billion surpassed the Zacks Consensus Estimate by 2.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SmileDirectClub (SDC) Q2 Loss Wider Than Expected, Margin Up
SmileDirectClub, Inc. reported a loss of 14 cents for second-quarter 2021, narrower than the year-ago loss of 25 cents. The figure was however wider than the Zacks Consensus Estimate of a loss of 10 cents.
Revenues
Revenues in the second quarter totaled $174.2 million, lagging the Zacks Consensus Estimate by 12%. However, the top line improved 62.7% from the year-ago number. The company shipped roughly 90,006 unique aligner orders, down 15.9% sequentially. The quarter’s ASP came in at $1,885, up 1.3% on a sequential basis.
Net revenues (related to retainers, whitening, and other ancillary products) came in at $20 million, primarily driven by the continued expansion of oral care products. Financing revenues (interest associated with SmilePay program) in the reported quarter were $12 million, flat compared to the last-reported quarter.
Margins
Gross profit in the reported quarter was $128.3 million, up 120% from the prior-year quarter. Gross margin of 73.7% expanded 1923 basis points (bps).
SmileDirectClub, Inc. Price, Consensus and EPS Surprise
SmileDirectClub, Inc. price-consensus-eps-surprise-chart | SmileDirectClub, Inc. Quote
Meanwhile, marketing and selling expenses rose 177.9% to $95.9 million. General and administrative expenses were $85 million, up 23.8% year over year. The company incurred adjusted operating loss of $52.7 million in the quarter. However, this was narrower than the year-ago operating loss of $44.9 million.
Financial Updates
SmileDirectClub exited the second quarter of 2021 with cash and cash equivalents of $376.6 million compared with $295.3 million at the end of the first quarter of 2021. Total debt (short and long-term) at the end of the second quarter was $744.1 million compared with $655.4 million at the end of first-quarter 2021.
Cumulative net cash flow used in operating activities at the end of the second quarter was $59.4 million compared with $85.8 million a year ago.
Guidance
SmileDirectClub has provided guidance for the year 2021.
For 2021, the company expects total revenues in the range of $750-$800 million. The Zacks Consensus Estimate for the same is pegged at $828.5 million.
Gross margin (as a percentage of total revenues) is expected in the mid-70% range through the second half of 2021.
Our Take
In the second quarter of 2021, SmileDirectClub achieved 62.7% year-over-year growth in total revenues. The company is currently expanding its teledentistry platform to dental and orthodontic offices through a collaborative model. A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives. Expansion of gross margin is encouraging. On the flip side, the company’s second-quarter adjusted loss was wider than the Zacks Consensus Estimate. Financing revenues were flat. The company incurred operating loss in the quarter. Escalating expenses are building pressure on the bottom line. A highly leveraged balance sheet is an added woe.
Zacks Rank and Key Picks
The company currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space that have announced their quarterly results are Encompass Health Corporation (EHC - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
Encompass Health, carrying a Zacks Rank #1 (Strong Buy), reported second-quarter 2021 adjusted earnings per share (EPS) of $1.17, which beat the Zacks Consensus Estimate by 15.8%. Revenues of $1.3 billion outpaced the consensus mark by 1.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2021 adjusted EPS of $2.46, which surpassed the Zacks Consensus Estimate by 41.4%. Revenues of $723.6 million outpaced the Zacks Consensus Estimate by 8.7%.
Henry Schein, carrying a Zacks Rank #2, reported second-quarter 2021 adjusted EPS of $1.11, surpassing the Zacks Consensus Estimate by 16.8%. Revenues of $2.97 billion surpassed the Zacks Consensus Estimate by 2.7%.